Pete - It is normal behavior for later phase trials. For open-label PhI, company has much more flexibility and can opt for cohort update pr's. This company is running this trial more like a PhII in their sitting on info. There may be reason for that - looks better in eyes of FDA and better for publication if  PhI  so closely guarded. Will help if they go for orphan drug status.